Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up
Annals of Internal Medicine · 2025-03 · 178 (3) · 348-359
DOI: 10.7326/annals-24-01015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Internal Medicine, 2025-03. Verfasst von George N Ioannou und 19 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development and Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System, and Division of Gastroenterology, Univers…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Vaccine Efficacy, SARS-CoV-2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: HSRD VA.
Abstract (Originalsprache)
BACKGROUND: Monovalent COVID-19 vaccines targeting the XBB.1.5 Omicron variant were introduced in September 2023. In the absence of randomized controlled trials demonstrating their efficacy, information on real-world vaccine effectiveness (VE) is needed. OBJECTIVE: To determine XBB.1.5 COVID-19 VE and the extent to which it declines over time. DESIGN: Target trial emulation. SETTING: U.S. Veterans Health Administration. PARTICIPANTS: Eligible XBB.1.5 vaccine recipients were matched 1:1 to unvaccinated persons in 7 sequential biweekly trials with enrollment from 2 October 2023 through 3 January 2024. INTERVENTION: XBB.1.5 COVID-19 vaccination versus no XBB.1.5 vaccination. MEASUREMENTS: Outcomes were ascertained through 10 May 2024 and included any positive result on a SARS-CoV-2 test from day 10 after the matched index date, subsequent hospitalization within 1 day before or 10 days after the positive result, or death within 30 days after the positive result. Vaccine effectiveness was estimated as 100 × (1 - risk ratio). RESULTS: Participants (91.3% male; mean age, 69.9 years) included 587 137 pairs of vaccinated and matched unvaccinated persons. Over a mean follow-up of 176 days (range, 118 to 211 days), VE was -3.26% (95% CI, -6.78% to -0.22%) against documented SARS-CoV-2 infection, 16.64% (CI, 6.47% to 25.77%) against SARS-CoV-2-associated hospitalization, and 26.61% (CI, 5.53% to 42.32%) against SARS-CoV-2-associated death. When estimated at 60, 90, and 120 days, respectively, VE against documented infection (14.21%, 7.29%, and 3.15%), hospitalization (37.57%, 30.84%, and 25.25%), or death (54.24%, 44.33%, and 30.25%) showed substantial waning. LIMITATION: Potential for residual confounding and incomplete capture of COVID-19 vaccination and SARS-CoV-2-related outcomes. CONCLUSION: COVID-19 vaccines targeting the XBB.1.5 variant of Omicron were not effective in preventing infection and had relatively low VE against hospitalization and death, which declined rapidly over time. PRIMARY FUNDING SOURCE: U.S. Department of Veterans Affairs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research and Development and Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System, and Division of Gastroenterology, University of Washington, Seattle, Washington (G.N.I.).
- Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, Washington (K.B.).
- Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, and Yale Center for Medical Informatics, Yale School of Medicine, New Haven…
- Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut (Y.L.).
- Veterans Affairs Cooperative Studies Program Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, and Department of Biostatistics, Yale School of Public Health, New Haven, C…
- Veterans Affairs Portland Health Care System, Portland, Oregon (D.B.).
ORCID-Profile: George N Ioannou, Nallakkandi Rajeevan, Lei Yan, Yuan Huang, Denise M Hynes, Edward J Boyko, Theodore J Iwashyna, Matthew L Maciejewski, Valerie A Smith, Theodore S Z Berkowitz, Elizabeth M Viglianti, Kristina L Bajema
Förderung
- HSRD VA
Zitieren
APA
Ioannou, G. N., Berry, K., Rajeevan, N., Li, Y., Yan, L., Huang, Y., Lin, H. M., Bui, D., Hynes, D. M., Rowneki, M., Bohnert, A., Boyko, E. J., Iwashyna, T. J., Maciejewski, M. L., Smith, V. A., Berkowitz, T. S. Z., O'Hare, A. M., Viglianti, E. M., Aslan, M., & Bajema, K. L. (2025). Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up. Annals of Internal Medicine, 178(3), 348-359. https://doi.org/10.7326/annals-24-01015
Vancouver
Ioannou GN, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, et al. Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up. Annals of Internal Medicine. 2025;178(3):348-359. doi:10.7326/annals-24-01015
BibTeX
@article{Ioannou2025,
author = {Ioannou, George N and Berry, Kristin and Rajeevan, Nallakkandi and Li, Yuli and Yan, Lei and Huang, Yuan and Lin, Hung-Mo and Bui, David and Hynes, Denise M and Rowneki, Mazhgan and Bohnert, Amy and Boyko, Edward J and Iwashyna, Theodore J and Maciejewski, Matthew L and Smith, Valerie A and Berkowitz, Theodore S Z and O'Hare, Ann M and Viglianti, Elizabeth M and Aslan, Mihaela and Bajema, Kristina L},
title = {Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up},
journal = {Annals of Internal Medicine},
year = {2025},
volume = {178},
number = {3},
pages = {348--359},
doi = {10.7326/annals-24-01015}
}
EUVIMED